Abstract: Tetrapeptide L-alanyl-L-glutamyl-L-asparagyl-L-proline of the general formula L-Ala-L-Glu-Asp-L-Pro is proposed as a biologically active compound stimulating the functional activity of neurones. The application of L-Ala-L-Glu-L-Asp-L-Pro tetrapeptide in medicine is proposed for the preparation of a drug stimulating the functional activity of neurones. There is proposed a pharmacological agent, which contains as its active base an effective amount of L-Ala-L-Glu-L-Asp-L-Pro tetrapeptide for its salts of the amino acid group (acetate, hydrochloride, oxalate) or its salts of carboxyl groups (the salts of sodium, potassium, calcium, lithium, zinc, magnesium, and also the salts of organic and inorganic cations-ammonium, triethylammonium). The agent is proposed for parenteral, intranasal and oral administration.

Abstract: Tetrapeptide L-alanyl-L-glutamyl-L-aspartyl-glycine (SEQ ID NO: 1) of the general formula L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO: 1) is proposed as a biologically active compound with a geroprotective effect. The use of L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO: 1) tetrapeptide in medicine is proposed for preparing a substance displaying a geroprotective effect. There is proposed a pharmacological substance, which contains as its active base an effective amount of tetrapeptide of the formula L-alanyl-L-glutamyl-L-aspartyl-glycine (L-Ala-L-Glu-L-Asp-Gly) (SEQ ID NO: 1) or its salts of the amino group (acetate, hydrochloride, oxalate) and of carboxyl groups (the salts of metals-Sodium, Potassium, Calcium, Lithium, Zinc, Magnesium, and also the salts of organic and inorganic cations-ammonium and triethylammonium). The substance is proposed for parenteral, intranasal, oral administration, and local application.

Abstract: Pharmaceutical compositions and methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient peptides having the formula R′-L-Glx-L-Glx-L-Lys-R″ and/or their pharmaceutically acceptable salts; wherein Glx is Gln or Glu.

Abstract: Pharmaceutical compositions and methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient peptides having the formula R′-L-Glx-L-Glx-L-Lys-R″ and/or their pharmaceutically acceptable salts; wherein Glx is Gln or Glu.

Abstract: This invention provides peptides of the formula R'-Glx-Glx-Lys-R" in which Glx is Glu or Gln. In particular, this invention provides the peptides Thr-Ala-Glu-Glu-Lys and Thr-Pro-Glu-Glu-Lys. This invention also provides pharmaceutical compositions comprising these peptides. The peptides of this invention are useful for immunomodulation.

Abstract: This invention provides methods of modulating the immune system by administering peptides of the formula R'-Glx-Glx-Lys-R" (SEQ ID NO:1) in which Glx is Glu or Gln. In particular, this invention provides the use of peptides Thr-Ala-Glu-Glu-Lys (SEQ ID NO:34) and Thr-Pro-Glu-Glu-Lys (SEQ ID NO:33).

Abstract: A pharmaceutical preparation for the therapy of immune deficiency conditions comprising an active principle--a peptide of the structure: H-L-Glu-L-Trp-OH and a pharmaceutically acceptable vehicle.

Abstract: A pharmaceutical preparation for the therapy of immune deficiency conditions comprising an active principle--a peptide of the structure: H-L-Glu-L-Trp-OH and a pharmaceutically acceptable vehicle.

Abstract: A pharmaceutical preparation for the therapy of immune deficiency conditions comprising an active principle--a peptide of the structure: H-L-Glu-L-Trp-OH and a pharmaceutically acceptable vehicle.

Abstract: A thymus-gland preparation is provided which contains polypeptides with a molecular weight of 600-6,000 Dalton and has the following composition, in percent by weight:______________________________________ polypeptides with an isoelectric point 80-90 of 3.5-6.7 polypeptides with an isoelectric point 20-10. of 7-9 and a molecular weight of 2,000-4,000 Dt ______________________________________A method for the production of the thymus-gland preparation is also provided and comprises homogenization of thymus tissue, extraction of the resulting homogenizate with a 1-10% aqueous solution of acetic acid in the presence of zinc chloride for at least 24 hours, separation of the resulting extract into a precipitate and a supernatant liquid which is treated with an organic solvent, followed by isolation of the desired product.